|
1）Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007; 25: 5233-9
|
|
|
|
2）von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006; 95: 966-73
|
|
|
|
|
|
3）肺癌診療ガイドライン2013年度版．http://www.haigan.gr.jp
|
|
|
|
|
|
4）Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer. 2006; 52: 155-63
|
|
|
|
|
|
5）Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel or observation. J Clin Oncol. 2003; 21: 2933-9
|
|
|
|
|
|
6）Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 499-506
|
|
|
|
|
|
7）Soon YY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009; 27: 3277-83
|
|
|
|
|
|
8）Lima JP, dos Santos LV, Sasse EC, et al. Optimal duration of first-line chemotherapy for advanced non-small-cell lung cancer: a systematic review with meta-analysis. Eur J Cancer. 2009; 45: 601-7
|
|
|
|
|
|
9）Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27: 591-8
|
|
|
|
|
|
10）Ciuleanu T, Brodowics T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind phase 3 study. Lancet. 2009; 374: 1432-40
|
|
|
|
|
|
11）Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo controlled phase 3 study. Lancet Oncol. 2010; 11: 521-9
|
|
|
|
|
|
12）Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomized controlled trial. Lancet Oncol. 2012; 13: 247-55
|
|
|
|
|
|
13）Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26: 3543-51
|
|
|
|
|
|
14）Obasaju C, Bowman L, Wang P, et al. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN). Ann Oncol. 2013; 24: 1534-42
|
|
|
|
|
|
15）Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non- small cell lung cancer with mutated EGFR. N Eng J Med. 2010; 362: 2380-8
|
|
|
|
|
|
16）Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13: 239-46
|
|
|
|
|
|
17）Perol M, Chouaid C, Perol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small cell lung cancer. J Clin Oncol. 2012; 30: 3516-24
|
|
|
|
|
|
18）Coudert B, Ciuleanu T, Park K, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol. 2012; 23: 388-94
|
|
|
|
|
|
19）Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doubled chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group Trial (WJTOG 0203). J Clin Oncol. 2009; 28: 753-60
|
|
|
|
|
|
20）Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomized phase 3 trial. Lancet Oncol. 2012; 13: 466-75
|
|
|
|
|
|
21）Gaafar RM, Surmont VF, Scagliotti GV, et al. A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). Eur J Cancer. 2011; 47: 2331-40
|
|
|
|
|
|
22）Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-50
|
|
|
|
|
|
23）Reck M, von Pawel, Zatloukal P, et al. Overall survival with cisplatin- gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol. 2010; 21: 1804-9
|
|
|
|
|
|
24）Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomized, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013; 24: 20-30
|
|
|
|
|
|
25）Galetta D, Pisconti S, Cinieri S, et al. First-line pemetrexed plus cisplatin followed by maintenance pemetrexed versus carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced nonsquamous NSCLC: a quality-of-life-oriented, multicenter randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale). J Clin Oncol. 2013; 31 (suppl) abstr 8071
|
|
|
|
|
|
26）Zinner R, Ross HJ, Weaver R, et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous non-small cell lung cancer (NS-NSCLC). J Clin Oncol. 2013; 31 (suppl) abstr 8003
|
|
|
|
|
|
27）Rittmeyer A, Scherpereel A, Gorbunova VA, et al. Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial. J Clin Oncol. 2013; 31 (suppl) abstr 8014
|
|
|
|
|
|
28）Patel JD, Socinski MA, Garon EB, et al. A randomized, open-label, phase III, superiority study of pemetrexed (Pem) + carboplatin (Cb) + bevacizumab (Bev) followed by maintenance Pem + Bev versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev in patients with stage IIIB or IV nonsquamous non-small cell lung cancer (NS-NSCLC). J Thoracic Oncol. 2012; 7(9) S336LBP1
|
|
|
|
|
|
29）Okamoto I, Aoe K, Kato T, et al. Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer. Invest New Drugs. 2013; 31: 1275-82
|
|
|
|
|